[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @3in5saved 3in5saved 3in5saved posts on X about $39b, $amgn, $162b, $37b the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1721917839534170112/interactions)  - X Month XXX -XX% - X Months XXXXX +5.90% - X Year XXXXX -XX% ### Mentions: X [#](/creator/twitter::1721917839534170112/posts_active)  ### Followers: XXX [#](/creator/twitter::1721917839534170112/followers)  - X Week XXX +13% - X Month XXX +14% - X Months XXX +29% - X Year XXX -XX% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1721917839534170112/influencer_rank)  ### Social Influence [#](/creator/twitter::1721917839534170112/influence) --- **Social category influence** [stocks](/list/stocks) XX% [currencies](/list/currencies) XX% **Social topic influence** [$39b](/topic/$39b) 20%, [$amgn](/topic/$amgn) #39, [$162b](/topic/$162b) 20%, [$37b](/topic/$37b) 20%, [$azn](/topic/$azn) #85, [$258b](/topic/$258b) 20%, [all the](/topic/all-the) 20%, [mcap](/topic/mcap) XX% **Top accounts mentioned or mentioned by** [@streetcred2017](/creator/undefined) [@biotechtradersd](/creator/undefined) [@yboyrov](/creator/undefined) [@bionavgator](/creator/undefined) [@barda](/creator/undefined) **Top assets mentioned** [Amgen, Inc. (AMGN)](/topic/$amgn) [AstraZeneca PLC (AZN)](/topic/$azn) ### Top Social Posts [#](/creator/twitter::1721917839534170112/posts) --- Top posts by engagements in the last XX hours "I think Amgen took their shot underestimated InflaRx biotech capabilities now a race to hopefully break even. Doubt they would sink more billions into this space. When AstraZeneca bought Alexion back in 2021 for $39b it came with Alexion blockbusters Soliris (eculizumab) and Ultomiris (ravulizumab) anti-C5 biotech of preclinical work that started way back in the 1990s. Thats a lot of time to be thinking about indications applicable to C5a-C5aR1 signaling. Over those decades of R&D it would seem likely that they also explored targeting the axis components but for whatever reason never got" [X Link](https://x.com/3in5saved/status/1980967928997593164) [@3in5saved](/creator/x/3in5saved) 2025-10-22T12:02Z XXX followers, XX engagements "@StreetCred2017 @YBoyrov @Bionavgator @BARDA $AMGN too at $162b. They liked a C5aR1 inhibitor (avacopan) enough to bid $3.7b for ChemoCentryx when the drug got approval to treat neutrophilic disease AAV. Seems C5aR1 inhibitor INF904 is quite the bargain. For now" [X Link](https://x.com/3in5saved/status/1980754175236374617) [@3in5saved](/creator/x/3in5saved) 2025-10-21T21:52Z XXX followers, XXX engagements "Party E: $AZN AstraZeneca ($258b mcap) I uploaded all the bidding details to both GPT and Grok requesting best guesses for each party. Then I asked Grok to review GPTs guesses against its guesses and then arrive at a final table; same for GPT of Groks guesses. Here are the final tables GPT then Grok with the following comments: GPT: Groks framework is quite credible especially for Party E = AstraZeneca and Party B = Roche which align with both transaction logic and historical behaviors. The main divergence is Party A where the Novartis link is just too strong to ignore and Party D where CSL" [X Link](https://x.com/3in5saved/status/1980847537641701870) [@3in5saved](/creator/x/3in5saved) 2025-10-22T04:03Z XXX followers, XXX engagements "@BioTechTraderSD What of the fundamentals though as to truth. What do you think about the role of neutrophils in disease severity of HS and the associated significance of C5a-C5aR1 signaling" [X Link](https://x.com/3in5saved/status/1981021853247283405) [@3in5saved](/creator/x/3in5saved) 2025-10-22T15:36Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@3in5saved 3in5saved
3in5saved posts on X about $39b, $amgn, $162b, $37b the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Month XXX -XX%
- X Months XXXXX +5.90%
- X Year XXXXX -XX%
Mentions: X #
Followers: XXX #
- X Week XXX +13%
- X Month XXX +14%
- X Months XXX +29%
- X Year XXX -XX%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XX% currencies XX%
Social topic influence $39b 20%, $amgn #39, $162b 20%, $37b 20%, $azn #85, $258b 20%, all the 20%, mcap XX%
Top accounts mentioned or mentioned by @streetcred2017 @biotechtradersd @yboyrov @bionavgator @barda
Top assets mentioned Amgen, Inc. (AMGN) AstraZeneca PLC (AZN)
Top Social Posts #
Top posts by engagements in the last XX hours
"I think Amgen took their shot underestimated InflaRx biotech capabilities now a race to hopefully break even. Doubt they would sink more billions into this space. When AstraZeneca bought Alexion back in 2021 for $39b it came with Alexion blockbusters Soliris (eculizumab) and Ultomiris (ravulizumab) anti-C5 biotech of preclinical work that started way back in the 1990s. Thats a lot of time to be thinking about indications applicable to C5a-C5aR1 signaling. Over those decades of R&D it would seem likely that they also explored targeting the axis components but for whatever reason never got"
X Link @3in5saved 2025-10-22T12:02Z XXX followers, XX engagements
"@StreetCred2017 @YBoyrov @Bionavgator @BARDA $AMGN too at $162b. They liked a C5aR1 inhibitor (avacopan) enough to bid $3.7b for ChemoCentryx when the drug got approval to treat neutrophilic disease AAV. Seems C5aR1 inhibitor INF904 is quite the bargain. For now"
X Link @3in5saved 2025-10-21T21:52Z XXX followers, XXX engagements
"Party E: $AZN AstraZeneca ($258b mcap) I uploaded all the bidding details to both GPT and Grok requesting best guesses for each party. Then I asked Grok to review GPTs guesses against its guesses and then arrive at a final table; same for GPT of Groks guesses. Here are the final tables GPT then Grok with the following comments: GPT: Groks framework is quite credible especially for Party E = AstraZeneca and Party B = Roche which align with both transaction logic and historical behaviors. The main divergence is Party A where the Novartis link is just too strong to ignore and Party D where CSL"
X Link @3in5saved 2025-10-22T04:03Z XXX followers, XXX engagements
"@BioTechTraderSD What of the fundamentals though as to truth. What do you think about the role of neutrophils in disease severity of HS and the associated significance of C5a-C5aR1 signaling"
X Link @3in5saved 2025-10-22T15:36Z XXX followers, XXX engagements